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High-dose cyclophosphamide given early after allogeneic hemopoietic cell transplantation has been shown to
be effective prophylaxis against graft-versus-host disease (GVHD) in the setting of HLA-matched myeloa-
blative bone marrow grafts, allowing avoidance of long-term immunosuppression with calcineurin inhibitors
in some patients. Whether this approach is feasible using granulocyte colonyestimulating factor (G-CSF)
emobilized peripheral blood stem cell grafts is unknown. We conducted an exploratory phase 2 trial of
cyclophosphamide given at 50 mg/kg i.v. on days 3 and 4 after transplantation as sole GVHD prophylaxis in
recipients of G-CSFemobilized peripheral blood stem cell grafts from HLA-matched related or unrelated
donors after reduced-intensity conditioning therapy with ﬂudarabine, carmustine, and melphalan. Five pa-
tients, ages 52 to 67 years, with high-risk hematologic malignancies were enrolled. Four of the 5 developed
severe acute GVHD of grades 3 to 4, requiring treatment with methylprednisolone and cyclosporine; 3 were
steroid refractory and were given salvage therapy. One of these 4 patients died of hepatic GVHD, one died of
sepsis, and 2 survived. We conclude that post-transplantation cyclophosphamide is inadequate as sole GVHD
prophylaxis in the context of peripheral blood reduced-intensity conditioning transplantations from HLA-
matched donors. This trial is registered at ACTRN12613001154796.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION also have high aldehyde dehydrogenase levels when acti-
Graft-versus-host disease (GVHD) remains a major
obstacle for the success of allogeneic hemopoietic cell
transplantation. Despite decades of preclinical and clinical
research, there is an ongoing risk of acute and chronic GVHD,
even with full molecular matching for human leukocyte
antigens (HLA) between donor and recipient. Prophylactic
strategies include the use of calcineurin inhibitors, drugs that
inhibit proliferating T lymphocytes, monoclonal and poly-
clonal antibodies against human T lymphocytes, and tech-
niques to physically deplete the stem cell graft of donor T
cells (recently reviewed in [1]). An alternative strategy
developed at Johns Hopkins University is the use of high
doses of cyclophosphamide early after stem cell infusion [2].
This is based on the premise that cyclophosphamide can
delete alloreactive donor T lymphocytes, which are induced
to proliferate soon after transplantation, thereby inducing
tolerance [3]. Hemopoietic stem cells, which express high
levels of the enzyme aldehyde dehydrogenase that is
responsible for metabolism of cyclophosphamide, are resis-
tant to the drug [4]. Recently, it has been shown that regu-
latory T cells, which play a role in inhibiting GVHD reactions,dgments on page 943.
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These observations led to clinical studies of GVHD pro-
phylaxis using cyclophosphamide on days 3 and 4 after
transplantation, either as a single agent in HLA-matched
transplantations using bone marrow from relatives or
volunteer unrelated donors [2,6], or with additional tacroli-
mus and mycophenolate mofetil in haploidentical related
donor marrow transplantations [7]. These encouraging
single-institution results led to a multicenter conﬁrmatory
study in the United States, where patients who received
myeloablative conditioning therapy with ﬂudarabine and
intravenous busulphan and a bone marrow graft from an
HLA-matched relative or unrelated donor were given 2 doses
of cyclophosphamide on days 3 and 4 after transplantation as
sole GVHD prophylaxis [8]. In 92 enrolled patients, the inci-
dence of grades 3 and 4 acute GVHD was 15%, comparable
with historical data using calcineurin inhibitorebased
therapy.
Peripheral blood stem cell grafts, mobilized by gran-
ulocyte colonyestimulating factor (G-CSF) treatment of do-
nors and collected by leukapheresis, are now widely used
instead of harvested bone marrow, but have been shown in
some studies to result in higher rates of acute and chronic
GVHD [9-12]. The interaction between G-CSFemobilized
grafts and post-transplantation cyclophosphamide has not
beenwidely studied. We and others have reported that post-
transplantation cyclophosphamide, given with subsequent
tacrolimus and mycophenolate mofetil, was effective in
preventing serious acute GVHD in patients receiving
Table 1
Patient Characteristics and Outcomes
Patient ID Sex/Age,
yr
Diagnosis Donor CD34
Dose, 106
per kg
CD3
Dose, 106
per kg
GVHD
Onset,
d
Organ/
Stage
Outcome
1426 F 56 AML CR1 MUD 6.0 146 NA NA Alive
1430 F 67 NHL CR1 MSD 6.0 119 90 S 3 GI 3 Dead
1438 F 67 AML CR1 MUD 5.0 224 34 GI 3 L 4 Dead
1439 M 52 AML REL1 MSD 5.4 238 27 S 2 GI 3 L4 Alive
1443 M 57 PH þ ALL MUD 4.2 183 21 S 2 L 4 Dead
F indicates female; AML, acute myeloid leukemia; CR1, ﬁrst complete remission; MUD, matched unrelated donor; NA, not applicable; NHL, non-Hodgkin
lymphoma; MSD, matched sibling donor; S, skin; GI, gastrointestinal; L, liver; M, male; REL1, relapse 1; PH þ ALL, Philadelphia chromosomeepositive acute
lymphoblastic leukemia.
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tives [13-16]. We therefore conducted a trial of post-
transplantation cyclophosphamide as sole GVHD prophy-
laxis in patients receiving HLA-matched peripheral blood
stem cell grafts. We chose a reduced-intensity conditioning
regimen as this is the type most commonly used at our
center, and we considered that only 1 regimen should be
used for purposes of clarity.PATIENTS AND METHODS
This was a prospective phase 2 clinical trial conducted at Westmead
Hospital to evaluate the safety and efﬁcacy of post-transplantation cyclo-
phosphamide as GVHD prophylaxis in HLA-matched peripheral blood stem
cell transplantations. The trial was approved by the human research ethics
committee of the Western Sydney Local Health District and is registered at
ACTRN12613001154796. All patients provided written consent after reading
an approved information form. Eligibility criteria consisted of patient ages
between 15 and 70 years, a diagnosis of high-risk hematological malignancy
requiring allogeneic hematopoietic cell transplantation, availability of either
a fully HLA-matched sibling donor (matched for HLA-A, -B, and -DRB1) or an
unrelated donor matched at allele level for HLA-A, -B, -C and -DRB1, absence
of serious organ dysfunction, and negativity for HIV and hepatitis B and C.
Reduced-intensity conditioning therapy consisted of ﬂudarabine 30 mg/
m2 i.v. daily for 4 days on days 5 to 2, carmustine 200 mg/m2/day i.v.
(adjusted to 150 mg/m2/day for patients 55 years of age and over) for 2 days
on days 4 and 3, and melphalan 140 mg/m2 i.v. (adjusted to 110 mg/m2
for patients 55 years and over) on day1, as previously described [17,18]. An
unmanipulated G-CSFemobilized peripheral blood stem cell graft from an
HLA-identical donor was given on day 0. Cyclophosphamide 50 mg/kg was
given i.v. on days þ3 and þ4, together with equivalent doses of mesna
administered 1 hour after each cyclophosphamide dose. No other GVHD
prophylaxis was given. Patients were managed in the outpatient clinic
during conditioning therapy and only admitted after transplantation for
management of complications. Supportive care consisted of transfusions
with red cell and platelet concentrates, pretransplantation ganciclovir i.v.
from day 8 to 4 if cytomegalovirus (CMV) seropositive, then monitoring
with PCR on blood and pre-emptive ganciclovir if CMV viremia occurred,
cotrimoxazole from day 9 to 2 before transplantation for Pneumocystis
jiroveci prophylaxis, and acyclovir 800 mg twice daily and ﬂuconazole 400
mg daily as herpes virus and yeast prophylaxis, respectively.
Acute GVHD was diagnosed on clinical grounds and histopathological
examination of affected tissues and staged according to modiﬁed Keystone
criteria [19]. Treatment of acute GVHD consisted of i.v. cyclosporine 1.5 mg/
kg every 12 hours and i.v. methylprednisolone 2 mg/kg daily. Patients failing
to respond after 7 to 14 days were given salvage therapy with horse antieT
cell globulin (ATGAM [Pﬁzer, New York, NY]) 15 mg/kg daily for 5 days and
etanercept 25 mg subcutaneously twice weekly for 4 weeks.
The design of the study was an exploratory phase 2 trial, with a pro-
jected accrual of 24 patients over 2 years. The primary study endpoint was
the rate of grades 3 and 4 acute GVHD occurring by day 100 after trans-
plantation, with secondary endpoints being the rate of all grades of acute
GVHD, the requirement for additional immunosuppression, the incidence of
chronic GVHD, relapse rate, treatment-related mortality at 100 days and at 1
and 2 years, and overall and progression-free survival at 2 years. The trial
was monitored by an independent committee. The stopping rules for the
trial were based on an historical observed rate of grades 3 and 4 acute GVHD
of 13% for HLA-matched transplantations, using the same conditioning
regimen and GVHD prophylaxis with rabbit antithymocyte globulin (Fre-
senius, Sydney, Australia), cyclosporine, and mycophenolate mofetil. The
protocol called for a review of data every three months by the monitoringcommittee and closure of the study if 4 or more cases of grades 3 or 4 acute
GVHDwere observed in the ﬁrst 12 patients enrolled. This boundary is based
on the charts of Mehta and Cain [20], and is consistent with a 95% conﬁ-
dence of an underlying rate of grades 3 and 4 GVHD of 13% or lower [20].
Otherwise, accrual would proceed to 24 patients.
RESULTS
A total of 5 patients were enrolled on this trial between
July and October 2014 before its early closure. Demographic
and disease details are given in Table 1. There were 3 females
and 2 males, ages 52 to 67 years (median, 57 years) at
transplantation. Diagnoses were acute myeloid leukemia
(n ¼ 3), Philadelphia chromosomeepositive acute lympho-
blastic leukemia (n ¼ 1), and high-grade non-Hodgkin lym-
phoma (n ¼ 1). All were in morphological remission at the
time of transplantation, except for patient 1439 who un-
derwent transplantation in early untreated ﬁrst relapse of
acute myeloid leukemia. All patients and their donors were
CMV-seropositive, except for patient 1439, who was sero-
negative with a seronegative unrelated donor. Stem cell
grafts contained 4.2 to 6.0 106 CD34þ cells/kg (median, 5.4)
and 119 to 238  106 CD3þ cells/kg (median, 183).
All patients engrafted, with median times to neutrophil
counts of .5 and 1.0  109/L of 18 (range, 15 to 26) and 22
(range, 16 to 27) days, respectively, and median time to
platelet count 20  109/L of 29 (range, 17 to 41) days. All 5
patients required admission for treatment of post-
transplantation complications, including 2 with brief ad-
missions to the intensive care ward for treatment of sepsis
and hypotension. The ﬁrst patient enrolled had no evidence
of acute GVHD when evaluated on day 100 after trans-
plantation and required no additional immunosuppression.
However, the subsequent 4 patients developed acute GVHD
at 21 to 90 days (median, 30 days) after transplantation.
Three had skin involvement, 3 had gastrointestinal involve-
ment, and 3 had hepatic disease. All were conﬁrmed on bi-
opsies of affected organs, including 2 by transjugular liver
biopsy. One patient (1430) had concurrent relapse of high-
grade lymphoma, conﬁrmed on mediastinal lymph node
biopsy.
Patient 1430 developed a rash and diarrhea on day þ90,
and this patient was started on cyclosporine and methyl-
prednisolone 2 mg/kg daily on day 93. There was improve-
ment in the rash, but there was persistent diarrhea, and the
patient died of septicemia on day 102. Patient 1438 had
vomiting and diarrhea on day þ34 and was started on
methylprednisolone 2 mg/kg on day þ37, with cyclosporine
being added on dayþ41. Therewas progression of GVHD and
salvage therapy was started on day þ51; however, there was
no response and the patient died on day þ80. Patient 1439
presented with rash on day þ27 and was started on meth-
ylprednisolone 2 mg/kg on day þ 31. Cyclosporin was added
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salvage therapy started on day þ47, when there was further
progression. The patient responded and is alive at dayþ 120.
Finally, patient 1443 had a rash and elevated bilirubin at
day þ31. He was given methylprednisolone 2 mg/kg on
day þ33, with cyclosporine being added at day þ 44. The
bilirubin continued to rise and salvage therapy was started
on day þ50. He failed to respond and died of liver failure on
day 100.
In view of the occurrence of 4 cases of severe acute GVHD
in the ﬁrst 5 cases treated on this protocol, the trial moni-
toring committee recommended closure of the study. Based
on a 13% failure rate, the probability of 4 failures in the ﬁrst 5
cases is .0012, and to be consistent with a 13% failure rate
over the whole trial would require at most 2 failures in the
next 19 patients (based on the upper 1-sided 95% conﬁdence
interval for a binomial proportion), which was considered to
be highly unlikely.
DISCUSSION
This clinical trial demonstrates that post-transplantation
high-dose cyclophosphamide is inadequate as sole GVHD
prophylaxis in the context of the use of G-CSFemobilized
peripheral blood stem cell grafts from HLA-matched related
or unrelated donors after reduced-intensity conditioning
therapy. The high rate of severe acute GVHD observed
mandated closure of the study and contrasts with the
outcome reported recently in a multicenter setting where
post-transplantation cyclophosphamide was studied using
bone marrow rather than G-CSFemobilized blood as the
stem cell source [8]. The conditioning therapy used in that
trial was essentially myeloablative, with 4 doses of i.v.
busulphan being given, rather than reduced intensity as in
our study. We cannot exclude the possibility that the choice
of regimens was a factor in the major difference in rates of
severe acute GVHD observed in the 2 studies. However,
although the onset of acute GVHD may be delayed after
reduced-intensity transplantations [21], there is no
convincing evidence to suggest an increased risk of acute
GVHD compared with that of myeloablative regimens [22]. It
is more likely that the difference in the rate of grades 3 and 4
acute GVHDwas due to the type of stem cell product used. G-
CSFemobilized blood stem cell products typically contain at
least 10-fold higher numbers of CD3þ donor lymphocytes
than marrow, increasing the risk of both acute and chronic
GVHD.
The impact of the use of G-CSFemobilized blood on GVHD
risk has been most extensively studied in the context of
myeloablative conditioning therapy. A meta-analysis of 9
randomized trials comparing bone marrow with mobilized
blood in matched sibling transplantations showed no dif-
ference in acute GVHD of all grades between the 2 stem cell
sources, but an increased rate of grades 3 and 4 acute GVHD
in the peripheral blood group was observed, with an odds
ratio of 1.39 [9]. In contrast, in a large retrospective registry
study, whereas peripheral blood grafts conveyed higher risks
of acute GVHD grades 2 to 4 as well as 3 and 4 in patients
under 40 years of age, the converse was true in older pa-
tients, with bone marrow being associated with higher
GVHD risk [23]. In transplantations using matched unrelated
donors, a registry study showed higher rates of grades 2 to 4
acute GVHD with peripheral blood grafts, although the rate
of severe grades was similar between blood and bone
marrow groups [10]. In a more recent registry analysis
examining the interaction between a number of clinicalvariables, in particular graft source and conditioning in-
tensity, peripheral blood grafts from matched siblings had a
lower risk of acute GVHD grades 2 to 4 than bone marrow for
patients receiving reduced-intensity regimens, whereas for
unrelated donor grafts, the converse was true [11]. These
studies generally support the notion of an increased risk of
acute GVHD with peripheral blood grafts, although other
variables such as donor type, conditioning intensity, and
GVHD prophylaxis inﬂuence outcomes.
Recently, Solomon et al. from Atlanta reported a small
single-center study in HLA-matched transplantations using
myeloablative conditioning therapy and G-CSFemobilized
blood stem cell grafts [24]. GVHD prophylaxis consisted of
post-transplantation cyclophosphamide followed by siroli-
mus, with no calcineurin inhibitor or other agents. Rates of
acute GVHD grades 2 to 4 and grades 3 and 4 were 46% and
15%, respectively, and chronic GVHD occurred in 31%. A
switch to tacrolimus was required in 31%. The authors
concluded that post-transplantation cyclophosphamide fol-
lowed by single-agent sirolimus provided adequate GVHD
prophylaxis, without the need for calcineurin inhibitor
therapy.
Finally, it should be noted that post-transplantation
cyclophosphamide followed by tacrolimus and mycophe-
nolate provides adequate protection against severe acute
GVHD in haploidentical related transplantations, even with
the use of peripheral blood grafts. We conclude that the use
of additional prophylactic agents, such as tacrolimus or
sirolimus, will be necessary to provide adequate immune
suppression if post-transplantation cyclophosphamide is to
be used with HLA-matched peripheral blood stem cell
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Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) en-
zymes for its cytotoxicity. We evaluated the inﬂuence of single nucleotide polymorphisms (SNPs) of CYP
enzymes on the efﬁcacy of autologous hematopoietic cell transplantation (HCT) for lymphoma. SNPs of 22
genes were analyzed in 93 patients with Hodgkin (n ¼ 52) and non-Hodgkin lymphoma (n ¼ 41) treated with
high-dose Cy followed by autologous HCT between 2004 and 2012. Preparative regimens contained Cy
(120 mg/kg) combined with carmustine/etoposide (n ¼ 61) or Cy (6000 mg/m2) with total body irradiation
(n ¼ 32). Lack of complete remission as measured by pretransplant positron emission tomography was the
sole clinical factor associated with increased risk of relapse (HR, 2.1). In genomic analysis, we identiﬁed a
single SNP (rs3211371) in exon 9 (C > T) of the CYP2B6 gene (allele designation 2B6*5) that signiﬁcantly
impacted patient outcomes. After adjusting for disease status and conditioning regimen, patients with the
CYP2B6*1/*5 genotype had a higher 2-year relapse rate (HR, 3.3; 95% CI, 1.6 to 6.5; P ¼ .041) and decreased
overall survival (HR, 13.5; 95% CI, 3.5 to 51.9; P ¼ .008) than patients with the wild-type allele. Two-year
progression-free survival for patients with 2 hypofunctional CYP2B6 variant genotypes (*5 and *6) was
only 11% (95% CI, 1% to 39%) compared with 67% (95% CI, 55% to 77%) for patients with the wild-type CYP2B6*1
allele in exon 9. Our results suggest that CYP2B6 SNPs inﬂuence the efﬁcacy of high-dose Cy and signiﬁcantly
reduce the success of autologous HCT for lymphoma patients with the CYP2B6*5 variant.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemo-/radiotherapy with autologous he-
matopoietic cell transplantation (HCT) often cures patients
with recurrent chemotherapy-sensitive lymphoma. Although
most patients attain remission after autologous HCT, disease
progression is the most common cause of treatment failure,
